ArticleNature genetics2021
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Nature genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 142 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 1 pooled it
14.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 1 synthesis or guideline pooled it, 189 citations in OpenAlex.
- Meningioma animal models: a systematic review and meta-analysis.Journal of translational medicine · 2023Pooled it
- An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy.Cancer research · 2025Trial
- A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.HemaSphere · 2026Article
- Review
- Harnessing human tumor organoids for cancer modeling and precision therapy.Protein & cell · 2026Review
- A Novel Perfused Full-Thickness Human Skin Microphysiological System for Modeling Injury, Regeneration, Tumor Pathophysiology, and Therapeutics Development.Advanced healthcare materials · 2026Article
- A medium throughput approach for single cell copy number variation sequencing towards efficient application in clinics.Journal of advanced research · 2026Article
- Single cell spatial transcriptomics track the evolutionary hierarchy and microenvironment remodeling during breast carcinoma invasion.Nature communications · 2026Article
- Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.Nature communications · 2026Article
- Tumoral switch in NUMB splicing changes essential transcription pathways and induces malignant properties in tumour cells.Genome biology · 2026Article
- Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.Molecular cancer · 2026Review
- Continuous Flow Paper Spray Ionization Mass Spectrometry for In-Depth Characterization of Anticancer Drugs in Tissues: Addressing Mass Spectral Complexity.Journal of the American Society for Mass Spectrometry · 2026Article
- Establishment of a Large-Scale PDX Library of Head and Neck Cancers for Functional Precision Oncology.Cancer medicine · 2026Article
- The functional imperative in high-grade glioma.Experimental & molecular medicine · 2026Review
- Resveratrol Nanoformulations for Cancer Management: A Comprehensive Review of Disease-Specific Strategies and Clinical Translational Barriers.International journal of nanomedicine · 2026Review
- Advancing cancer research: Cutting-edge insights from colorectal cancer patient-derived xenograft mouse models.Genes & diseases · 2026Review
- Comprehensive DNA profiling strategy for patient-derived xenograft model authentication in the J-PDX library.Scientific reports · 2025Article
- A Feasibility Study of Co-Established Patient-Derived Subcutaneous Xenograft and Organotypic Slice Cultures in Hormone-Naive Primary Prostate Cancer Preclinical Modeling: A Single-Institution Experience.Life (Basel, Switzerland) · 2025Article
- Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor Models.Cancer research communications · 2025Article
- High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models.Nature communications · 2025Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
64 authors at 17 institutions in 9 countries.
Xing Yi Woo *The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.ORCID http://orcid.org/0000-0002-5980-4383
Jessica Giordano *Department of Oncology, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0003-0204-8158
Anuj SrivastavaThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Zi-Ming ZhaoThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Michael W LloydThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Roebi de BruijnNetherlands Cancer Institute, Amsterdam, the Netherlands.
Yun-Suhk SuhCollege of Medicine, Seoul National University, Seoul, Republic of Korea.
Rajesh PatidarFrederick National Laboratory for Cancer Research, Frederick, MD, USA.
Li ChenFrederick National Laboratory for Cancer Research, Frederick, MD, USA.
Sandra SchererDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Matthew H BaileyDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Chieh-Hsiang YangDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Emilio Cortes-SanchezDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Yuanxin XiDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5398-0802
Jayamanna WickramasingheThe Wistar Institute, Philadelphia, PA, USA.
Andrew V KossenkovThe Wistar Institute, Philadelphia, PA, USA.
Vito W RebeccaThe Wistar Institute, Philadelphia, PA, USA.
Hua SunDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
R Jay MashlDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Sherri R DaviesDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-7141-8354
Ryan JeonSeven Bridges Genomics, Charlestown, MA, USA.
Christian FrechSeven Bridges Genomics, Charlestown, MA, USA.
Jelena RandjelovicSeven Bridges Genomics, Charlestown, MA, USA.
Jacqueline RosainsSeven Bridges Genomics, Charlestown, MA, USA.
Francesco GalimiDepartment of Oncology, University of Turin, Turin, Italy.
Andrea BertottiDepartment of Oncology, University of Turin, Turin, Italy.
Adam LaffertyDepartment of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Alice C O'FarrellDepartment of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID http://orcid.org/0000-0002-6732-2966
Elodie ModaveCenter for Cancer Biology, VIB, Leuven, Belgium.
Diether LambrechtsCenter for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3429-302X
Petra Ter BruggeNetherlands Cancer Institute, Amsterdam, the Netherlands.
Violeta SerraVall d´Hebron Institute of Oncology, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6620-1065
Elisabetta MarangoniDepartment of Translational Research, Institut Curie, PSL Research University, Paris, France.ORCID http://orcid.org/0000-0002-3337-6448
Rania El BottyDepartment of Translational Research, Institut Curie, PSL Research University, Paris, France.
Hyunsoo KimThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Jong-Il KimCollege of Medicine, Seoul National University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-7240-3744
Han-Kwang YangCollege of Medicine, Seoul National University, Seoul, Republic of Korea.
Charles LeeThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Dennis A DeanSeven Bridges Genomics, Charlestown, MA, USA.ORCID http://orcid.org/0000-0002-7621-9717
Brandi Davis-DusenberySeven Bridges Genomics, Charlestown, MA, USA.
Yvonne A EvrardFrederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-3475-4850
James H DoroshowDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Alana L WelmDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-1412-1351
Bryan E WelmDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Michael T LewisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Bingliang FangDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jack A RothDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8955-1313
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Meenhard HerlynThe Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0839-0739
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0977-0912
Li DingDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Shunqiang LiDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Ramaswamy GovindanDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Claudio IsellaDepartment of Oncology, University of Turin, Turin, Italy.
Jeffrey A MoscowInvestigational Drug Branch, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0479-1693
Livio TrusolinoDepartment of Oncology, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0002-6379-3365
Annette T ByrneDepartment of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Jos JonkersNetherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-9264-9792
Carol J BultThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Enzo MedicoDepartment of Oncology, University of Turin, Turin, Italy. enzo.medico@unito.it.ORCID http://orcid.org/0000-0002-3917-2438
Jeffrey H ChuangThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. jeff.chuang@jax.org.ORCID http://orcid.org/0000-0002-3298-2358
PDXNET Consortium
EurOPDX Consortium
Jackson Laboratory · USCandiolo Cancer Institute · ITSeven Bridges Genomics (United States) · USThe University of Texas MD Anderson Cancer Center · USUniversity of Utah · USWashington University in St. Louis · USThe Wistar Institute · USFrederick National Laboratory for Cancer Research · USRoyal College of Surgeons in Ireland · IESeoul National University · KRThe Netherlands Cancer Institute · NLNational Cancer Institute · USUniversité Paris Sciences et Lettres · FRVIB-KU Leuven Center for Cancer Biology · BEBaylor College of Medicine · USEwha Womans University · KRVall d'Hebron Institute of Oncology · ES
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MWashington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6MShared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MResearch Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Jessie Villanueva · 2017 to 2026
$13.9MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5MWashington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft ModelsU54CA224083 · NCI · WASHINGTON UNIVERSITY · PI Brian Andrew Van Tine · 2017 to 2026
$13.0MWashington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9MCancer Research UK 29567CCR NIH HHS HHSN261200800001CNational Centre for the Replacement, Refinement and Reduction of Animals in Research NC/T001267/1NCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201400008CNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA034196NCI NIH HHS P30 CA042014NCI NIH HHS P30 CA091842NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA196510NCI NIH HHS R50 CA211199NCI NIH HHS U24 CA204781NCI NIH HHS U24 CA224067NCI NIH HHS U54 CA224065NCI NIH HHS U54 CA224070NCI NIH HHS U54 CA224076NCI NIH HHS U54 CA224083NCI NIH HHS U54 CA233223NCI NIH HHS U54 CA233306NHGRI NIH HHS T32 HG008962
Abstract
Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical studies and therapeutic testing. It has been proposed that the mouse host affects tumor evolution during PDX engraftment and propagation, affecting the accuracy of PDX modeling of human cancer. Here, we exhaustively analyze copy number alterations (CNAs) in 1,451 PDX and matched patient tumor (PT) samples from 509 PDX models. CNA inferences based on DNA sequencing and microarray data displayed substantially higher resolution and dynamic range than gene expression-based inferences, and they also showed strong CNA conservation from PTs through late-passage PDXs. CNA recurrence analysis of 130 colorectal and breast PT/PDX-early/PDX-late trios confirmed high-resolution CNA retention. We observed no significant enrichment of cancer-related genes in PDX-specific CNAs across models. Moreover, CNA differences between patient and PDX tumors were comparable to variations in multiregion samples within patients. Our study demonstrates the lack of systematic copy number evolution driven by the PDX mouse host.
Indexed as
Xenograft Model Antitumor AssaysAnimalsDatabases, GeneticDNA Copy Number VariationsExome SequencingGene Expression Regulation, NeoplasticHumansMiceNeoplasm MetastasisPolymorphism, Single Nucleotide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.